D-1115-2018 Class II

Recalled by Hetero Labs Limited Unit V — Jadcherla Mandal, Mahaboob Nagar

FDA drug recall D-1115-2018 was initiated by Hetero Labs Limited Unit V on Aug 8, 2018 and is designated Class II. Reason for recall: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. Affected quantity: 441,408 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 29, 2018
Initiation Date
Aug 8, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
441,408 bottles

Product description

Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854 By: Hetero Hetero Labs Limited, Unit V, Pollepally Jadcherla Mahabubnagar - 509-301, India. NDC 31722-747-90 UPC 331722747905

Reason for recall

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Distribution pattern

Nationwide

Code information

All Lots with expiration dates 7/2018 to 6/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1115-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1115-2018. Report a data issue: hello@regdatalab.com.